Preoperative rapid suppression of viral load by elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide regimen in human immunodeficiency virus-positive fracture patients significantly reduces postoperative complications.
作者信息
Ma Rui, Zhang Qiang, Zhang Yao-Shen, Xu Biao, Tong Zhi-Wen, Zhao Chang-Song, Zhao Ru-Gang
机构信息
Department of Orthopedics, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Department of Orthopedics, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
出版信息
Chin Med J (Engl). 2020 Dec 5;133(23):2892-2893. doi: 10.1097/CM9.0000000000001185.
Abstract
摘要
相似文献
1
Preoperative rapid suppression of viral load by elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide regimen in human immunodeficiency virus-positive fracture patients significantly reduces postoperative complications.在人类免疫缺陷病毒阳性骨折患者中，使用埃替拉韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺方案术前快速抑制病毒载量可显著降低术后并发症。
Chin Med J (Engl). 2020 Dec 5;133(23):2892-2893. doi: 10.1097/CM9.0000000000001185.
2
Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis.艾维雷韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺单片复方制剂用于人类免疫缺陷病毒暴露后预防。
Clin Infect Dis. 2020 Feb 14;70(5):943-946. doi: 10.1093/cid/ciz577.
3
Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.在初治的 HIV 感染青少年中，含有艾维雷韦、考比司他、恩曲他滨和替诺福韦艾拉酚胺的单片复方制剂的安全性、疗效和药代动力学：一项单臂、开放标签试验。
Lancet HIV. 2016 Dec;3(12):e561-e568. doi: 10.1016/S2352-3018(16)30121-7. Epub 2016 Oct 17.
4
A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.捷扶康（艾维雷韦、考比司他、恩曲他滨和替诺福韦艾拉酚胺）用于治疗HIV-1感染的疗效和安全性综述
J Pharm Pract. 2018 Apr;31(2):216-221. doi: 10.1177/0897190017710519. Epub 2017 May 30.
5
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide discontinuation and return to normal weight.依维莫司/考比司他/恩曲他滨/替诺福韦艾拉酚胺停药并恢复正常体重。
Int J STD AIDS. 2021 Jan;32(1):92-95. doi: 10.1177/0956462420964341. Epub 2020 Nov 11.
6
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results.简要报告：替诺福韦艾拉酚胺与富马酸替诺福韦二吡呋酯随机双盲比较，二者均与埃替格韦、考比司他和恩曲他滨联合用于初治HIV-1感染：第96周结果
J Acquir Immune Defic Syndr. 2016 May 1;72(1):58-64. doi: 10.1097/QAI.0000000000000940.
7
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.第 96 周疗效和安全性结果：评估从强化蛋白酶抑制剂加恩曲他滨/替诺福韦二吡呋酯方案转换为达芦那韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺（D/C/F/TAF）每日一次单片方案在治疗经验丰富、病毒学抑制的 HIV-1 成人中的疗效和安全性。
Antiviral Res. 2019 Oct;170:104543. doi: 10.1016/j.antiviral.2019.104543. Epub 2019 Jul 4.
8
Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial.一项多中心、开放标签、3b 期、随机试验：在 HIV-1 病毒学抑制的 60 岁及以上人群中，将包含富马酸替诺福韦二吡呋酯的方案转换为艾维雷韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺单片复方制剂方案时，对骨矿物质密度的影响。
Lancet HIV. 2019 Oct;6(10):e655-e666. doi: 10.1016/S2352-3018(19)30195-X.
9
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.艾维雷韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺：用于治疗人类免疫缺陷病毒 1 型感染的综述。
Drugs. 2016 Jun;76(9):957-68. doi: 10.1007/s40265-016-0586-z.
10
Switching from efavirenz to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide reduces central nervous system symptoms in people living with HIV.从依非韦伦转换为艾维雷韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺可减少 HIV 感染者的中枢神经系统症状。
Chin Med J (Engl). 2021 Oct 13;134(23):2850-2856. doi: 10.1097/CM9.0000000000001824.
引用本文的文献
1
ERAS perioperative management measures in total hip replacement in HIV-positive patients with osteonecrosis of the femoral head.人工关节置换术围手术期管理措施在 HIV 阳性合并股骨头坏死患者中的应用
J Orthop Surg Res. 2024 Nov 23;19(1):787. doi: 10.1186/s13018-024-05255-0.
2
The consensus guideline of perioperative antiviral therapy for AIDS patients in China based on clinical practice.基于临床实践的中国艾滋病患者围手术期抗病毒治疗专家共识指南。
Front Med (Lausanne). 2023 Dec 6;10:1267236. doi: 10.3389/fmed.2023.1267236. eCollection 2023.
3
Analysis of the efficacy of drilling decompression autologous bone marrow and allogeneic bone grafting in the treatment of HIV-positive patients with early osteonecrosis of the femoral head.分析钻孔减压自体骨髓和同种异体骨移植治疗 HIV 阳性早期股骨头坏死患者的疗效。
BMC Musculoskelet Disord. 2023 Nov 21;24(1):902. doi: 10.1186/s12891-023-07039-9.
本文引用的文献
1
Antiretroviral drug use by individuals living with HIV/AIDS and compliance with the Clinical Protocol and Therapy Guidelines.艾滋病毒/艾滋病感染者使用抗逆转录病毒药物情况以及对临床方案和治疗指南的依从性。
Einstein (Sao Paulo). 2020 Feb 17;18:eAO4995. doi: 10.31744/einstein_journal/2020AO4995. eCollection 2020.
2
HIV virologic response better with single-tablet once daily regimens compared to multiple-tablet daily regimens.与每日多片用药方案相比，每日单片用药方案的HIV病毒学应答更佳。
SAGE Open Med. 2018 Dec 4;6:2050312118816919. doi: 10.1177/2050312118816919. eCollection 2018.
3
A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.捷扶康（艾维雷韦、考比司他、恩曲他滨和替诺福韦艾拉酚胺）用于治疗HIV-1感染的疗效和安全性综述
J Pharm Pract. 2018 Apr;31(2):216-221. doi: 10.1177/0897190017710519. Epub 2017 May 30.
4
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.简要报告：替诺福韦艾拉酚胺（TAF）与富马酸替诺福韦二吡呋酯（TDF）分别与埃替拉韦、考比司他和恩曲他滨（E/C/F）联合用于初治HIV-1感染的随机、双盲比较：第144周结果
J Acquir Immune Defic Syndr. 2017 Jun 1;75(2):211-218. doi: 10.1097/QAI.0000000000001350.
5
Outcomes of acutely HIV-1-infected individuals following rapid antiretroviral therapy initiation.急性HIV-1感染个体在快速启动抗逆转录病毒治疗后的结果。
Antivir Ther. 2017;22(1):77-80. doi: 10.3851/IMP3080. Epub 2016 Sep 2.
Zotero 插件